Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

SpringWorks Therapeutics, Inc. - common stock (NQ: SWTX )

55.13 +1.13 (+2.09%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,303,919
Open 53.75
Bid (Size) 58.50 (9)
Ask (Size) 58.70 (2)
Prev. Close 54.00
Today's Range 50.81 - 56.62
52wk Range 28.21 - 60.00
Shares Outstanding 49,127,913
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+52.80%
+52.80%
1 Month
+48.96%
+48.96%
3 Month
+66.81%
+66.81%
6 Month
+47.64%
+47.64%
1 Year
+20.08%
+20.08%

More News

Read More
Germany's Merck In Talks To Buy Cancer Drug Maker SpringWorks Therapeutics
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Crude Oil Rises Sharply; Manhattan Associates Shares Slide
Via Benzinga
Exposures Fossil Fuels
Smart Money Is Betting Big In SWTX Options
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
Springworks Stock Soars To Nearly 3-Year High On Buyout Buzz, Retail Sentiment Rockets
Via Stocktwits
Nasdaq Surges 1%; ON Semiconductor Shares Plunge Following Earnings Miss
Via Benzinga
Rockwell Automation Posts Upbeat Earnings, Joins Insperity, BP, Alibaba And Other Big Stocks Moving Higher On Monday
Via Benzinga
SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
SpringWorks Therapeutics Stock Sees RS Rating Jump To 86
Via Investor's Business Daily
SpringWorks Therapeutics Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates at 43rd Annual J.P. Morgan Healthcare Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Plug Power, Capri And Frontline Are Among Top Mid Cap Gainers Last Week (Jan 6-10): Are The Others In Your Portfolio?
Via Benzinga
SpringWorks Therapeutics Stock Gets A RS Rating Lift
Via Investor's Business Daily
SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics Announces Mirdametinib Data to be Presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors to be Presented at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
FDA Grants Priority Review to SpringWorks Therapeutics’ New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.